Figure 2.
In vivo evaluation of imatinib efficacy in KITV560D and KITK642E mutant PDX models. (A-B) Inhibition efficacy of imatinib in PDX models with KITV560D mutation (n= 5 mice per group). Imatinib, 50 mg/kg, tumor growth inhibition, TGI= 25.04%, P>0.05; imatinib, 100 mg/kg, TGI= 35.81%, P >0.05, Student's t-test. (C-D) Inhibition efficacy of imatinib in PDX models with KITK642E mutation (n=6 mice per group). Imatinib, 100 mg/kg, TGI = 35.81%, Student's t-test, P > 0.05.